JP2020522544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522544A5 JP2020522544A5 JP2019567608A JP2019567608A JP2020522544A5 JP 2020522544 A5 JP2020522544 A5 JP 2020522544A5 JP 2019567608 A JP2019567608 A JP 2019567608A JP 2019567608 A JP2019567608 A JP 2019567608A JP 2020522544 A5 JP2020522544 A5 JP 2020522544A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- antigen
- antibody
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023111915A JP2023123842A (ja) | 2017-06-09 | 2023-07-07 | Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517672P | 2017-06-09 | 2017-06-09 | |
| US62/517,672 | 2017-06-09 | ||
| US201762532162P | 2017-07-13 | 2017-07-13 | |
| US62/532,162 | 2017-07-13 | ||
| EP18305565 | 2018-05-04 | ||
| EP18305565.6 | 2018-05-04 | ||
| PCT/IB2018/054182 WO2018225041A1 (en) | 2017-06-09 | 2018-06-09 | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111915A Division JP2023123842A (ja) | 2017-06-09 | 2023-07-07 | Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522544A JP2020522544A (ja) | 2020-07-30 |
| JP2020522544A5 true JP2020522544A5 (https=) | 2021-07-26 |
Family
ID=62815099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567608A Pending JP2020522544A (ja) | 2017-06-09 | 2018-06-09 | Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 |
| JP2023111915A Pending JP2023123842A (ja) | 2017-06-09 | 2023-07-07 | Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111915A Pending JP2023123842A (ja) | 2017-06-09 | 2023-07-07 | Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3634469A1 (https=) |
| JP (2) | JP2020522544A (https=) |
| KR (1) | KR20200026826A (https=) |
| CN (1) | CN110913889A (https=) |
| AU (1) | AU2018280567A1 (https=) |
| CA (1) | CA3066317A1 (https=) |
| IL (2) | IL314423A (https=) |
| MX (1) | MX2019014831A (https=) |
| TW (2) | TW201904608A (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| SG192117A1 (en) | 2011-01-28 | 2013-08-30 | Sanofi Sa | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CN118105480A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| CN113876956B (zh) * | 2020-07-01 | 2023-07-04 | 陈敏 | Pcsk9抑制剂在制备促进皮肤色素生成产品中的应用 |
| CN114525258A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达pcsk9阻断物的多能干细胞或其衍生物及应用 |
| CN115992138A (zh) * | 2021-09-30 | 2023-04-21 | 北京安龙生物医药有限公司 | 用于治疗与pcsk9相关疾病的靶向寡核苷酸 |
| CN116236582A (zh) * | 2021-12-07 | 2023-06-09 | 广州嘉越医药科技有限公司 | 吲哚取代四氢异喹啉类化合物与他汀类化合物的联合应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| WO2015140079A1 (en) * | 2014-03-17 | 2015-09-24 | Sanofi | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
| CA2955304C (en) * | 2014-07-16 | 2023-12-12 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
| KR20230074283A (ko) * | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| JP2018523684A (ja) * | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
-
2018
- 2018-06-08 TW TW107119851A patent/TW201904608A/zh unknown
- 2018-06-08 TW TW111142924A patent/TW202310872A/zh unknown
- 2018-06-09 EP EP18737034.1A patent/EP3634469A1/en not_active Withdrawn
- 2018-06-09 KR KR1020197038159A patent/KR20200026826A/ko not_active Ceased
- 2018-06-09 IL IL314423A patent/IL314423A/en unknown
- 2018-06-09 AU AU2018280567A patent/AU2018280567A1/en not_active Abandoned
- 2018-06-09 JP JP2019567608A patent/JP2020522544A/ja active Pending
- 2018-06-09 CN CN201880037888.2A patent/CN110913889A/zh not_active Withdrawn
- 2018-06-09 CA CA3066317A patent/CA3066317A1/en active Pending
- 2018-06-09 IL IL271212A patent/IL271212B2/en unknown
- 2018-06-09 MX MX2019014831A patent/MX2019014831A/es unknown
-
2023
- 2023-07-07 JP JP2023111915A patent/JP2023123842A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522544A5 (https=) | ||
| Heuvelman et al. | Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes | |
| JP6379143B2 (ja) | エクセナチドの経口投与用の方法及び組成物 | |
| RU2494755C2 (ru) | Способы и композиции для перорального введения белков | |
| Shah et al. | Oral delivery of proteins: progress and prognostication | |
| US20080213288A1 (en) | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound | |
| US20140011733A1 (en) | Combination of acylated glucagon analogues with insulin analogues | |
| EP1515749B1 (en) | Combined use of a modulator of cd3 and a glp-1 compound | |
| KR20150047606A (ko) | 고혈당증 치료를 위한 방법 및 조성물 | |
| CN105963685A (zh) | 包含glp-1激动剂和n-(8-(2-羟基苯甲酰)氨基)辛酸盐的固体组合物 | |
| CN101505594A (zh) | 代谢紊乱的组合治疗 | |
| Mittermayer et al. | Addressing unmet medical needs in type 1 diabetes: a review of drugs under development | |
| TW201904608A (zh) | 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法 | |
| JP2014148524A (ja) | 持続性血糖降下剤の投与方法 | |
| RU2670106C2 (ru) | Фармацевтическая композиция | |
| Bahtiyar et al. | Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes | |
| Viljoen et al. | Glucagon-like peptide 1 therapy: from discovery to type 2 diabetes and beyond | |
| Umpierrez et al. | Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice | |
| Rendell | United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes | |
| JP2021523214A5 (https=) | ||
| Groves et al. | Standard and novel treatment options for metabolic syndrome and diabetes mellitus | |
| Nauck et al. | Incretin‐based therapies | |
| WO2018204918A1 (en) | Treatment of hepatic disorders | |
| Jeon et al. | Glucagon-like Peptide-1 Receptor Agonists | |
| TWI919251B (zh) | 使用gip/glp1共促效劑之療法 |